We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene Soars 47.8% in Six Months: Will the Rally Continue?
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) has been in investor’s good books on the back of solid revenue stream and acquisitions.
This Zacks Rank #3 (Hold) company has surged 47.8% in the past six months, outperforming its industry’s increase of 12.8%. The performance looks brighter in comparison to other companies’ stock movement in the same space, such as Molina Healthcare, Inc (MOH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem, Inc. , which have gained 39.6%, 32.9% and 3.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
This leading U.S. Health insurer has been witnessing consistent and significant revenue growth since 2002. The company’s top line witnessed a CAGR of 34.6% from 2015 to 2019. Its 2019 revenues shot up mainly on the back of the Fidelis Care buyout, growth in the Health Insurance Marketplace business and expansions plus new programs across many states in 2018 and 2019.
The company is steadily focused on contract wins and extension across different geographies over the past many years. Several initiatives contributed to its robust membership growth and we expect the same to continue going forward.
Moreover, mergers and acquisitions have always been its primary growth trajectory. In the second quarter of 2019, the company completed the acquisition of QCA Health Plan, Inc. and made a substantial investment in RxAdvance. Last July, it also purchased additional stakes in Ribera Salud, which makes it own 90% interest in the acquired entity, thereby boosting its international presence.
Further, Centene completed the pending buyout of WellCare, which strengthened its presence via wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members. In total, it has around 22 million members across 50 US states.
Will the Rally Continue?
We expect this industry giant’s outperformance to continue as it is well-poised for growth on the back of its solid fundamentals. Also, its long-term growth rate is pegged at 14.30%, higher than the industry’s average of 13.2%.
The company also boasts a stellar earnings surprise history, having outpaced the Zacks Consensus Estimate in all the trailing four quarters, the average being 3.3%. Such consistency level vouches for the company’s operating efficiency.
Moreover, the Zacks Consensus Estimate for current-year earnings indicates an 8.6% hike from the year-ago reported figure on revenues of $106.2 billion, which in turn, implies a 42.3% surge from the prior-year reported number.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Centene Soars 47.8% in Six Months: Will the Rally Continue?
Centene Corporation (CNC - Free Report) has been in investor’s good books on the back of solid revenue stream and acquisitions.
This Zacks Rank #3 (Hold) company has surged 47.8% in the past six months, outperforming its industry’s increase of 12.8%. The performance looks brighter in comparison to other companies’ stock movement in the same space, such as Molina Healthcare, Inc (MOH - Free Report) , Humana Inc. (HUM - Free Report) and Anthem, Inc. , which have gained 39.6%, 32.9% and 3.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
This leading U.S. Health insurer has been witnessing consistent and significant revenue growth since 2002. The company’s top line witnessed a CAGR of 34.6% from 2015 to 2019. Its 2019 revenues shot up mainly on the back of the Fidelis Care buyout, growth in the Health Insurance Marketplace business and expansions plus new programs across many states in 2018 and 2019.
The company is steadily focused on contract wins and extension across different geographies over the past many years. Several initiatives contributed to its robust membership growth and we expect the same to continue going forward.
Moreover, mergers and acquisitions have always been its primary growth trajectory. In the second quarter of 2019, the company completed the acquisition of QCA Health Plan, Inc. and made a substantial investment in RxAdvance. Last July, it also purchased additional stakes in Ribera Salud, which makes it own 90% interest in the acquired entity, thereby boosting its international presence.
Further, Centene completed the pending buyout of WellCare, which strengthened its presence via wider scale and diversification with more than 12 million Medicaid and around 5 million Medicare members. In total, it has around 22 million members across 50 US states.
Will the Rally Continue?
We expect this industry giant’s outperformance to continue as it is well-poised for growth on the back of its solid fundamentals. Also, its long-term growth rate is pegged at 14.30%, higher than the industry’s average of 13.2%.
The company also boasts a stellar earnings surprise history, having outpaced the Zacks Consensus Estimate in all the trailing four quarters, the average being 3.3%. Such consistency level vouches for the company’s operating efficiency.
Moreover, the Zacks Consensus Estimate for current-year earnings indicates an 8.6% hike from the year-ago reported figure on revenues of $106.2 billion, which in turn, implies a 42.3% surge from the prior-year reported number.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>